Medaysis
Enable Innovation

DATA SHEET

Rabbit Anti-SPOP/TEF2 Polyclonal: RC0060-0.1ML

Intended Use: For Research Use Only

Description: SPOP protein (speckle-type POZ protein), also known as TEF2, or HIB homolog 1, is a component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex which plays a crucial role in cellular processes by mediating the ubiquitination of target proteins, leading most often to their proteasomal degradation. SPOP undergoes ubiquitination and subsequent proteasomal degradation, highlighting a dynamic role in maintaining protein homeostasis within the cell. Nuclear expression of SPOP across various tissues underscores importance in cellular regulation and potential implications in disease processes, making SPOP antibody a valuable tool for researchers studying these mechanisms.

Specifications

Clone:	Polyclonal
Source:	Rabbit
Isotype:	IgG
Reactivity:	Human
Immunogen:	Recombinant human SPOP aa 48-374
Localization:	Nucleus, cytoplasm
Formulation:	Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC


Package:

Description	Catalog No.	Size
SPOP/TEF2 Polyclonal Concentrated	RC0060-0.1ML	0.1 ml

IHC Procedure*

Positive Control Tissue:	Adrenal gland, kidney, prostate, HNSCC, RCC
Concentrated Dilution:	10-200
Pretreatment:	Tris EDTA pH9.0, 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
Incubation Time and Temp:	Overnight at 4°C
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human adrenal gland stained with anti-SPOP using DAB

References:

1. Speckle-type POZ protein as a diagnostic biomarker in renal cell carcinoma. Ashutosh Chauhan, et al. J Cancer Res Ther. Jul-Sep;14(5):977-982, 2018. doi: 10.4103/jcrt.
2. Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1/sentrin specific peptidase. Piyou Ji, et al., Biochem Biophys Res Commun. Jul 7;502(1):30-42, 2018. doi: 10.1016/j.bbrc.2018.05.115.
3. Cancer Mutations of the Tumor Suppressor SPOP Disrupt the Formation of Active, Phase-Separated Compartments. Jill J. Bouchard, et al., Molecular Cell. Volume 72, Issue 1P19-36.E8 October 04, 2018.
4. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics. Hui Wang, et al. J Transl Med. Aug 15;15(1):175, 2017. doi: 10.1186/s12967-017-1276-7.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 510-509-3153 www.medaysis.com

© Medaysis Company